MAPT and Alzheimer disease: Finally, tau biomarker cutoffs used in Figure 1, which are hypothesized as being optimal to identify AD pathology, gave good to excellent specificity (97% for plasma, 95% for CSF, and 100% for PET), but low sensitivity (34%, 45%, and 17%, respectively) at identifying CU who will develop MCI.